Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of cytarabine and daunorubicin for myeloid leukemia in children with Down syndrome
NL-OMON58841Phase 3Suspended
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of cytarabine and daunorubicin in myeloid leukemia associated with Down syndrome (ML-DS) and myelodysplastic syndrome (MDS), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Event-free survival. Started Feb 2022; status: suspended.
02
Drugs
cytarabinedaunorubicin
03
Conditions
myeloid leukemia associated with Down syndrome (ML-DS)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON58841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58841.